Last Updated: November 9, 2026

ULTRAVIST 150 Drug Patent Profile

Name: ULTRAVIST 150 Drug Patent, Exclusivity, and Generic Launch Dataset
Creator: DrugPatentWatch
License: https://www.drugpatentwatch.com/terms.php

« Back to Dashboard

When do Ultravist 150 patents expire, and what generic alternatives are available?

Ultravist 150 is a drug marketed by Bayer Hlthcare and is included in one NDA.

The generic ingredient in ULTRAVIST 150 is iopromide. There is one drug master file entry for this compound. One supplier is listed for this compound. Additional details are available on the iopromide profile page.

AI Deep Research

Questions you can ask:

What is the 5 year forecast for ULTRAVIST 150?
What are the global sales for ULTRAVIST 150?
What is Average Wholesale Price for ULTRAVIST 150?

Summary for ULTRAVIST 150

US Patents:	0
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	1
Clinical Trials:	11
Patent Applications:	3,213
DailyMed Link:	ULTRAVIST 150 at DailyMed

Drug patent expirations by year for ULTRAVIST 150

Recent Clinical Trials for ULTRAVIST 150

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Duke Clinical Research Institute	Phase 4
GE Healthcare	Phase 4
Bayer	Phase 4

See all ULTRAVIST 150 clinical trials

Pharmacology for ULTRAVIST 150

Drug Class	Radiographic Contrast Agent
Mechanism of Action	X-Ray Contrast Activity

US Patents and Regulatory Information for ULTRAVIST 150

+ Get email alerts for changes to this table

Glossary

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Bayer Hlthcare	ULTRAVIST 150	iopromide	INJECTABLE;INJECTION	020220-004	May 10, 1995		DISCN	Yes	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Expired US Patents for ULTRAVIST 150

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Bayer Hlthcare	ULTRAVIST 150	iopromide	INJECTABLE;INJECTION	020220-004	May 10, 1995	⤷ Start Trial	⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>Patent No.	>Patent Expiration

International Patents for ULTRAVIST 150

See the table below for patents covering ULTRAVIST 150 around the world.

Subscribe to access the full database, or Start Trial
Country	Patent Number	Title	Estimated Expiration
Austria	1061		⤷ Start Trial
Australia	529565		⤷ Start Trial
Australia	5627280		⤷ Start Trial
Canada	1130316	DIAMIDES D'ACIDE ISOPHTALIQUE TRI-IODES UTILISES COMME AGENTS DE CONTRASTE NON IONIQUES POUR RAYONS X (TRI-IODATED ISOPHTHALIC ACID DIAMIDES AS NON-IONIC X-RAY CONTRAST AGENTS)	⤷ Start Trial
Czechoslovakia	226408	METHOD OF PREPARING TRIIODINATED DIAMIDES OF ISOPHTALIC ACID	⤷ Start Trial
>Country	>Patent Number	>Title	>Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.